Skip to main content
. 2018 Aug 7;8(16):4462–4476. doi: 10.7150/thno.24395

Figure 1.

Figure 1

(A) Schematic overview of the design of the dimeric conjugate and the mode of binding of the biparatopic affibody to VEGFR2, blocking the VEGF epitope. (B) Purity determination by analytical RP-HPLC for ZVEGFR2-Bp2. (C) LC-ESI/MS mass spectrum for ZVEGFR2-Bp2. The experimentally determined mass is indicated in the spectrum. (D) Determination of refolding capacity. CD spectra before and after heat treatment to 90 °C. (E) Determination of heat stability. CD ellipticity at 221 nm as a function of temperature.